Skip to main content

Table 2 Distribution of histone H3K18 and K14 acetylation and p300 in ccRCC tumor versus paired normal kidney according to tumor grade and stage [32, 41]

From: KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2

 

Normal kidney

ccRCC

T vsN

ccRCC G 1

ccRCC G ≥ 2

G1 vs G ≥ 2

ccRcc stage 1

ccRCC stage ≥ 2

Stage 1 vs stage ≥ 2

H3AcK14% mean ± SD

38.54 ± 29.33

34.26 ± 30.86

0.319

58.50 ± 24.605

24.56 ± 27.753

0.000

39.59 ± 32.583

24.04 ± 24.775

0.051

 Male

38.91 ± 32.31

34.85 ± 30.34

0.52

      

 Female

37.83 ± 23.36

33.13 ± 32.45

0.65

      

 M vs F

0.796

0.715

       

H3AcK18% mean ± SD

77.02 ± 19.99

68.51 ± 25.57

0.26

48.65 ± 22.335

76.46 ± 22.403

0.000

68.76 ± 25.848

68.04 ± 25.578

0.945

 Male

75.83 ± 22.91

66.91 ± 27.03

0.12

      

 Female

71.58 ± 22.74

71.58 ± 22.74

0.14

      

 M vs F

0.939

0.546

       

p300% mean ± SD

70.46 ± 23.46

67.73 ± 21.17

0.21

46.65 ± 17.388

76.16 ± 16.133

0.000

66.35 ± 22.584

70.38 ± 18.332

0.527

 Male

65.67 ± 20.32

72.67 ± 23.82

0.13

      

 Female

71.67 ± 22.63

66.29 ± 22.66

0.41

      

 M vs F

0.166

0.189